News

This S&P 500 stock could surge 55% in just 12 months, according to experts
One particular S&P 500 biotech continues to stink out our writer's Stocks and Shares ISA. Is it time he chucked in the towel? The post This S&P 500 stock could surge 55% in just 12 months, according ...
Analysts Conflicted on These Healthcare Names: Moderna (MRNA) and MiMedx Group (MDXG)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Moderna (MRNA – Research Report) and MiMedx Group (MDXG – Research Report). Elevate Your Inve ...
RBC Capital Keeps Their Hold Rating on Moderna (MRNA)
RBC Capital analyst Luca Issi maintained a Hold rating on Moderna on August 1 and set a price target of $28.00. The company’s shares closed last Friday at $27.61. Take advantage of TipRanks Premium at ...